Member Info for Jarv55

https://invst.ly/qpm4e
few gaps up to flll

Schools open in June this could be huge.

They are already supplying businesses this could be huge when the unlock the country

Filta Group Holdings PLC (AIM: FLTA), a provider of fryer management and other services to commercial kitchens, is pleased to announce the UK launch of FiltaShield, a new sanitising service to help businesses combat and prevent the spread of Coronavirus (COVID-19).



Working closely with industry experts and specialist chemical suppliers, Filta is extending its range of environmental services and deploying an approved, laboratory-tested Coronavirus sanitising solution, which is effective against all enveloped viruses, killing them within minutes. The anti-viral solution, which has been developed for use in restaurants, bars, shops, offices as well as healthcare facilities, is applied to a surface by spraying or fogging, leaving behind a mono-molecular layer that bonds to the surface and protects surfaces for up to 30 days.



In addition, as part of its service to tackle Coronavirus and help businesses and public bodies adapt to new safety requirements, Filta has teamed up with a technology supplier to supply and manage temperature screening devices for its customers, which can screen up to 30 people per second for a fever. The devices, which are installed at the entrances of buildings, provide operators with a further preventive measure against the spread of Coronavirus.





CEO of Filta Group, Jason Sayers said: "As companies look to open up again after the current lockdown, the safety of employees, visitors and clients will be a key focus.



"We are proud to have developed this highly effective service in such a short period, and are now helping businesses and organisations make the necessary preparations to get back up and running as quickly as possible.



"Filta has always sought to adapt to the needs of its customers, and has already seen a growing number of orders from existing clients, as well as interest from businesses outside of our traditional customer base of restaurants and hospitality. Whilst FiltaShield is currently only available in the UK, we will look to roll out this service in the U.S. and Europe in due course."

I hope it isn't Val its a dog

Well what a superb up lift in profits can see why they are trying to add to Belluscura.
https://www.prnewswire.com/news-releases/high-prevalence-of-copd-driving-growth-in-portable-oxygen-concentrators-market-over-2018-2026-transparency-market-research-301005842.html

https://www.nsmedicaldevices.com/news/uk-covid-19-antibody-testing/

Worth a listen https://www.youtube.com/watch?v=nCGGBRY4JQs

Harmonics

Quite a few possible ahrmonics on this https://invst.ly/qo5k8

StoneChecker: While we are currently pursuing strategic pathways to optimise the economic value of StoneChecker Software, we continue to enhance its basic functionality to help prepare it for widespread clinical adoption. During 2019, we incorporated an easy way to route CT dataset to the software. This feature mimics PACS retrieval capability common in the industry. In addition, an output reporting feature was developed that can be exported directly to a site's PACS.

Development of New Products

In 2019, we announced the development of several significant new product initiatives. To support these initiatives, the company enlisted key personnel to assist in both the core development of those products as well as provide business and regulatory support. Specifically, in late 2019 a recognized leader in Artificial Intelligence (AI) and Deep Learning applications was contracted and will be an integral factor in achieving our development goals.

· Longitudinal Delta T1 Maps: Using Image to identify areas of residual brain tumor after surgery is integral to the evaluation of treatment response and clinical decision-making. Despite continued developments in advanced imaging biomarkers, the selection of the contrast-agent enhancing (T1+C) tumor volume (or region of interest, ROI) will remain central to this process. Delta T1 maps were developed by IB to robustly determine enhancing tumor volumes. Using an exclusive technology termed "standardization", Delta T1 maps have the ability to cause a paradigm shift in how brain tumor burden is assessed before surgery and during treatment. To fully realize its potential, development efforts are underway to automate the segmentation of the residual enhancing volumes. Once automated, this quantitative information would be provided to the treatment team as a fundamental biomarker for any neuro exam containing a pre- and post-contrast image. The next logical step would then be to present this information over time, or longitudinally, in a concise report.



· Stroke Processing: In the latter half of 2019, IB announced the launch of a stroke imaging platform. This platform leverages our existing algorithms optimized for neuro application, and a stroke application represents the next logical extension of our product portfolio. In the US alone, stroke costs an estimated $34 billion annually. These costs include health care services, medicines to treat stroke, and lost days of work. While several competitors have strong market positions in stroke imaging, we believe an opportunity exists in streamlining the processing of the information and optimizing workflows using our existing software algorithms.

interesting
New information is emerging around the ever-changing landscape of the global COVID pandemic. Initially thought to only affect respiratory tracts, new findings offer evidence that COVID impacts major organ systems throughout the body. People between the ages of 20 and 50 and otherwise healthy are uncharacteristically experiencing (large-vessel) strokes after being diagnosed with the virus. Blood clots throughout the body are forming and migrating to the brain. At the time of publishing this Annual Report, it is still not clear how COVID-19 is causing blood clots. According to a New England Journal of Medicine (NEJM) publication, initial reports from Wuhan, China stated that approximately 5% of patients who were hospitalized with the coronavirus suffered a stroke. And, other clinicians are noticing abnormal clotting in a "significant minority" of intensive care unit patients with COVID-19.



Thus, clinicians specialising in neurological disorders are coming to the forefront, and IB's software solutions are available to help them in cases where stroke is suspected. IB's core products are renown for accurately computing a variety of MR and CT perfusion parameters in the brain which are directly applicable to stroke assessment. We intend to maintain a watchful eye as new findings about COVID-19 surface and, as a nimble and responsive company, potentially allocate resources to help clinicians combat this virus as best we can (or as appropriate).

This a buy hold and wait for a sale already collaborating with Astrazenica and Gsk

No short https://shorttracker.co.uk/

Interesting article https://www.bbc.co.uk/news/uk-scotland-44872432

Deepmatter is digitizing chemistry, making it recordable, reproducible and shareable

Our platform transforms chemistry into code. It uses Artificial Intelligence (AI) and Machine Learning (ML) to make better molecules and provide insights never before available.

https://www.deepmatter.io/

For the first time in 200 years we’re changing how chemistry is done.

Through the making, using and sharing of data, deepmatter liberates chemists to capture, record and discover together on a global scale.

Beyond the bench
Beyond the lab
Beyond the known

Fully funded last placing over subscribed at 2.5p £4million already getting contracts.